Diseases & Conditions
Grants & Contracts
News & Events
See the list of featured NIAID clinical trials below or view the complete list of NIAID studies recruiting participants on ClinicalTrials.gov.
Researchers at the National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID) seek healthy volunteers for a study looking at how common antibiotics affect the trillions of good microbes that live on and in our body, also known as our microbiome.
This 10- to 20-minute survey is available for patients with eczema or parents of patients with eczema. These questions will help us learn more about patient experiences to improve current research and guide future research.
NIAID is committed to advancing the understanding of how and why autoimmune diseases such as rheumatoid arthritis occur.
Airway irritation, cough and bronchial spasm are common symptoms in patients with airway inflammatory diseases such as asthma. The primary focus of this exploratory study is to determine if there is an increase in tissue temperature in airway mucosa during asthma exacerbation.
Determining how memory T helper type 2 (Th2) initiate recall responses to aeroallergens has the potential to change the therapeutic approach to allergic asthma, the most common asthma subtype.
There is a need for people to take part in research studies to learn more about diseases and how to treat them.
This will be a single site, mechanistic study of asthmatic subjects and healthy, non-asthmatic controls involving a baseline characterization visit and a research bronchoscopy visit.
This protocol describes a single site mechanistic study to investigate microRNAs (miRNAs) that are differentially expressed in the airway epithelium of patients with asthma at baseline and in response to allergen challenge.
The primary objective of this NIAID study is to further characterize the natural history of idiopathic CD4 lymphocytopenia (ICL).
This study will evaluate patients with abnormal immune function that results in recurrent or unusual infections or chronic inflammation.
To learn more about when and why IBD may develop in some people with primary immune dysregulation.
This study will determine the long term medical condition and daily functioning of participants with CGD after a transplant and if possible, compare these results to participants who do not undergo a transplant.
To see if RFA is a safe and effective treatment for CGD-related liver abscesses.
This study is a prospective non-controlled, non-randomized Phase I/II clinical trial to assess the safety, feasibility and efficacy of cellular gene therapy in patients with chronic granulomatous disease.
This protocol is designed to study the techniques needed to develop gene therapy or other treatments for certain inherited immune system diseases.
To collect data on people with primary immune deficiency disorders.
Currently, people with immune disorders fall outside of guidance for COVID-19 vaccination, as they are typically excluded from vaccine trials.
The goal of this study is to evaluate the safety and efficacy of BIO 300 Oral Suspension to improve lung function in patients that were previously hospitalized with COVID-19 related pulmonary complications.
The primary purpose of NIAID's ACTIV-5/BET study is to evaluate the efficacy of investigational therapeutics in adults hospitalized for COVID-19.
This is a national study that will compare the immune response to additional COVID‐19 vaccine doses in participants with autoimmune disease who did not mount an adequate response to the initial vaccination regimen.
A study to learn how coronavirus affects different organs of the body and the function of the body's immune system.
The NIAID Vaccine Research Center is looking for volunteers who are recovered from COVID-19 infection to donate blood for a research study.
The primary objectives of this study are to evaluate the safety and reactogenicity of delayed heterologous or homologous vaccine doses after Emergency Use Authorization (EUA)-dosed vaccines and to evaluate the breadth of the humoral immune responses of heterologous and homologous delayed boost re
This NIAID research study focuses on an experimental drug which may help treat COVID-19 by supporting the immune system.
Randomized, placebo-controlled, crossover study to assess risk of recurrence of allergic reactions in individuals who had an immediate systemic allergic reaction after 1st dose of an mRNA COVID-19 vaccine and aiming to explore the underlying mechanism(s) of these reactions.